China-based biotechnology company founded in 2008 that discovers and develops innovative therapies for chronic diseases, particularly metabolic disorders
China-based biotechnology company founded in 2008 that discovers and develops innovative therapies for chronic diseases, particularly metabolic disorders. Its pipeline includes peptide-based and other therapeutics for type 2 diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation, and congenital hyperinsulinemia. The company uses its HECTOR technology system and is developing GLP-1 receptor agonists and oral metabolic-disease medicines.